Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: A tissue doppler imaging study

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Naka, Katerina K ^a   Pappas, Konstantinos ^a   Papathanassiou, Katerina ^a   Papamichael, Nikolaos D ^a   Kazakos, Nikolaos ^a   Kanioglou, Chryssanthi ^a   Makriyiannis, Demetrios ^b   Katsouras, Christos S ^a   Liveris, Kostas ^a   Tsatsoulis, Agathocles ^a   Michalis, Lampros K ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b G HATZIKOSTA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TISSUE DOPPLER IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; VELOCITY; BLOOD PRESSURE; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; HEART FUNCTION TEST; HYPERGLYCEMIA; MIDDLE AGED; SYSTOLE; TREATMENT FAILURE;

AGED; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; HEART FUNCTION TESTS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MIDDLE AGED; SYSTOLE; THIAZOLIDINEDIONES; TREATMENT FAILURE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77956873665     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-57     Document Type: Article

References (34)

1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27:1879-1884. 10.2337/diacare.27.8.1879, 15277411.
2. Fonarow GC, Srikanthan P. Diabetic cardiomyopathy. Endocrinol Metab Clin North Am 2006, 35:575-599. 10.1016/j.ecl.2006.05.003, 16959587.
3. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007, 115:3213-3223. 10.1161/CIRCULATIONAHA.106.679597, 17592090.
4. Annonu AK, Fattah AA, Mokhtar MS, Ghareeb S, Elhendy A. Left ventricular systolic and diastolic functional abnormalities in asymptomatic patients with non-insulin-dependent diabetes mellitus. J Am Soc Echocardiogr 2001, 14:885-891. 10.1067/mje.2001.112892, 11547274.
5. Boyer J, Thanigaraj S, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004, 93:870-875. 10.1016/j.amjcard.2003.12.026, 15050491.
6. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106-1118. 10.1056/NEJMra041001, 15356308.
7. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee T, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001, 134:61-71.
8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289. 10.1016/S0140-6736(05)67528-9, 16214598.
9. Lincoff AM, Wolski K, Nichols SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188. 10.1001/jama.298.10.1180, 17848652.
10. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108:2941-2948. 10.1161/01.CIR.0000103683.99399.7E, 14662691.
11. Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005, 18:949-957. 10.1016/j.amjhyper.2005.02.003, 16053992.
12. van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009, 119:2069-2077. 10.1161/CIRCULATIONAHA.108.803916, 19349323.
13. Tsuji T, Mizushige K, Noma T, Murakami K, Ohmori K, Miyatake A, Kohno M. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 2001, 38:868-874. 10.1097/00005344-200112000-00008, 11707690.
14. Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev 2003, 19:487-493. 10.1002/dmrr.410, 14648808.
15. Sambanis C, Tziomalos K, Kountana E, Kakavas N, Zografou I, Balaska A, Koulas G, Karagiannis A, Zamboulis C. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol 2008, 45:23-30. 10.1007/s00592-007-0014-7, 17768592.
16. Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008, 14:445-452. 10.1016/j.cardfail.2008.02.007, 18672190.
17. Khouri SJ, Maly GT, Suh DD, Walsh TE. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 2004, 17:290-297. 10.1016/j.echo.2003.08.012, 14981433.
18. Terui G, Goto T, Katsuta M, Aoki I, Ito H. Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients. J Cardiol 2009, 54:52-58. 10.1016/j.jjcc.2009.03.004, 19632520.
19. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463. 10.1016/j.echo.2005.10.005, 16376782.
20. Møller JE, Egstrup K, Køber L, Poulsen SH, Nyvad O, Torp-Pedersen C. Prognostic importance of systolic and diastolic function after acute myocardial infarction. Am Heart J 2003, 145:147-153. 10.1067/mhj.2003.46, 12514667.
21. Papathanassiou K, Naka KK, Kazakos N, Kanioglou C, Makriyiannis D, Pappas K, Katsouras CS, Liveris K, Kolettis T, Tsatsoulis A, Michalis LK. Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis 2009, 205:221-226. 10.1016/j.atherosclerosis.2008.11.027, 19135671.
22. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. JAMA 2007, 298:1189-1195. 10.1001/jama.298.10.1189, 17848653.
23. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418. 10.1001/jama.2010.920, 20584880.
24. Dorkhan M, Dencker M, Frid A. Treatment with pioglitazone induced significant, reversible mitral regurgitation. Cardiovasc Diabetol 2008, 7:12. 10.1186/1475-2840-7-12, 2412844, 18445302.
25. Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. Cardiovasc Diabetol 2009, 8:15. 10.1186/1475-2840-8-15, 2664795, 19298680.
26. St John Sutton M, Rendell M, Dandona P, Dole J, Murphy K, Patwardhan R, Patel J, Freed M. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002, 25:2058-2064. 10.2337/diacare.25.11.2058, 12401757.
27. Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007, 49:1696-1704. 10.1016/j.jacc.2006.10.077, 17448371.
28. Biscetti F, Straface G, Arena V, Stigliano E, Pecorini G, Rizzo P, De Angelis G, Iuliano L, Ghirlanda G, Flex A. Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. Cardiovasc Diabetol 2009, 8:49. 10.1186/1475-2840-8-49, 2745363, 19737384.
29. von Bibra H, Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab Vasc Dis Res 2008, 5:310-318. 10.3132/dvdr.2008.045, 18958842.
30. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001, 37:1943-1949. 10.1016/S0735-1097(01)01230-X, 11401136.
31. Loimaala A, Groundstroem K, Rinne M, Nenonen A, Huhtala H, Vuori I. Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetes. Cardiovasc Ultrasound 2007, 5:32. 10.1186/1476-7120-5-32, 2094704, 17897465.
32. Vinereanu D, Nicolaides E, Tweddel AC, Madler CF, Holst B, Boden LE, Cinteza M, Rees AE, Fraser AG. Subclinical left ventricular dysfunction in asymptomatic patients with Type II diabetes mellitus, related to serum lipids and glycated haemoglobin. Clin Sci (Lond) 2003, 105:591-599. 10.1042/CS20030168, 12831396.
33. Jarnert C, Landstedt-Hallin L, Malmberg K, Melcher A, Ohrvik J, Persson H, Ryden L. A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study. Eur J Heart Fail 2009, 11:39-47. 10.1093/eurjhf/hfn018, 19147455.
34. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009, 10:165-193. 10.1093/ejechocard/jep007, 19270053.